今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

京剧大师毕谷云仙逝，享年九十三岁

上海，2023年1月7日 - 著名京剧表演艺术家、教育家毕谷云先生于今日17时49分在上海市第九人民医院病逝，享年九十三岁。毕谷云先生毕生致力于京剧艺术事业，在舞台上塑造了众多经典角色，为京剧艺术传承和发展做出了卓越贡献。他的逝世是京剧界的重大损失。

毕谷云先生1930年出生于上海，自幼酷爱京剧。1949年，他师从徐碧云女士学习京剧，打下了坚实的基础。新中国成立后，毕谷云先生曾任职于上海京剧院、上海戏剧学院等单位，并多次出访海外，为世界各地的观众传播京剧艺术。

毕谷云先生的嗓音条件优美，唱功精湛，表演细腻传神，在老生、青衣、花旦等行当均有建树，被誉为“全能型”京剧演员。他所主演的《霸王别姬》、《贵妃醉酒》、《梁山伯与祝英台》等剧目，深受观众喜爱。

毕谷云先生不仅是一位杰出的京剧表演艺术家，也是一位桃李满园的京剧教育家。他曾培养了众多优秀京剧演员，为京剧艺术传承做出了重要贡献。

毕谷云先生的逝世，是京剧界的重大损失。他的艺术成就将永远铭记于人们心中。

以下是对毕谷云先生艺术生涯的简要回顾：

• 1949年，师从徐碧云女士学习京剧。
• 新中国成立后，曾任职于上海京剧院、上海戏剧学院等单位。
• 多次出访海外，为世界各地的观众传播京剧艺术。
• 曾主演《霸王别姬》、《贵妃醉酒》、《梁山伯与祝英台》等剧目。
• 培养了众多优秀京剧演员，为京剧艺术传承做出了重要贡献。

毕谷云先生的逝世，再次提醒我们要珍惜和保护传统文化艺术。我们要继承和弘扬毕谷云先生的艺术精神，为京剧艺术的传承和发展贡献力量。